To assess the evidence underlying Hemoglobin A1c (HbA1c) in patients with hemoglobinopathy and the use of this modality to evaluate confounders, sources of error, upcoming developments and reach evidence-based conclusions on their optimal use in patients who require tight glucose control. This was a retrospective chart review of 7 patients with data collected between the years 2004 - 2009. Participants were selected based on the criteria that they were 1) diagnosed with Type 2 Diabetes Mellitus; 2) patients of the North Florida Thyroid Center for at least one year; and 3) had hemoglobinopathy. These patients were selected using electronic medical records (EMR). Researchers were blinded of patients’ gender, race and any other personal identifiers. A random search was performed for hemoglobinopathy within physician patient database. Assessing glycemia in diabetics can be a challenge, in particular subgroup patients with hemoglobinopathies face several pitfalls that can implicate glycemia assessment rather difficult. Our results suggest there may be a discrepancy between mean blood glucose and A1C levels of individuals with a hemoglobinopathy in small cohorts at risk of cardiovascular demise.
Published in | International Journal of Diabetes and Endocrinology (Volume 2, Issue 1) |
DOI | 10.11648/j.ijde.20170201.12 |
Page(s) | 5-9 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2017. Published by Science Publishing Group |
Cardiovascular, Diabetes, Glycemic, Hemoglobinopathy, HbA1c, Cardiothoracic
[1] | Adekanmbi J, Higgins T, Rodriguez-capote K, et al. Erroneous HbA1c results in a patient with elevated HbC and HbF. Clin Chim Acta. 2016; 462: 153-157. |
[2] | Behan KJ, Mbizo J, Johnston MA. Is the Correlation of HbA1c to Average Glucose Predictable in Individuals With Sickle Cell Trait? J Diabetes Sci Technol. 2015; 10 (1): 236-7. |
[3] | DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes. 1986; 35: 530-545. |
[4] | Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clinical Chemistry. 2001; 47 (2): 153–163. |
[5] | Dorland, W. A. (1965). Dorland s medical dictionary. Kentucky: APH. |
[6] | Greer JP, Arber DA, Rodgers GM. Wintrobe's Clinical Hematology. Amirsys; 2014. Disorders of red cells, 4 (33), 856-857 |
[7] | Herman, W. H., Ma, Y., Uwaifo, G., Haffner, S., Kahn, S. E., Horton, E. S., et al. (2007). Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care, 30 (10), 2453-2457. |
[8] | Melmed S, Williams RH. Williams Textbook of Endocrinology. Saunders; 2011. Type 2 Diabetes, 31 (6), 1404-1405 |
[9] | Saudek, C. D., Derr, R. L., & Kalyani, R. R. (2006). Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA: The Journal of the American Medical Association, 295 (14), 1688-1697. |
[10] | Smaldone, A. (2008). Glycemic control and hemoglobinopathy: When A1C may not be reliable. Diabetes Spectrum, 21 (1), 46-49. |
[11] | Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016; 11: 95-104. |
[12] | Subramaniam B, Lerner A, Novack V, et al. Increased glycemic variability in patients with elevated preoperative HbA1C predicts adverse outcomes following coronary artery bypass grafting surgery. Anesth Analg. 2014; 118 (2): 277-87. |
[13] | Tran, H., Silva, D., & Petrovsky, N. (2004). Case study: Potential pitfalls of using hemoglobin A1C as the sole measure of glycemic control. Clinical Diabetes, 22 (3), 141-143. |
APA Style
Clauden Louis. (2017). Assessment of Glycemic Control and Hemoglobinopathy: When HbA1c Testing Is Unreliable in High Risk Cardiovascular Patients. International Journal of Diabetes and Endocrinology, 2(1), 5-9. https://doi.org/10.11648/j.ijde.20170201.12
ACS Style
Clauden Louis. Assessment of Glycemic Control and Hemoglobinopathy: When HbA1c Testing Is Unreliable in High Risk Cardiovascular Patients. Int. J. Diabetes Endocrinol. 2017, 2(1), 5-9. doi: 10.11648/j.ijde.20170201.12
@article{10.11648/j.ijde.20170201.12, author = {Clauden Louis}, title = {Assessment of Glycemic Control and Hemoglobinopathy: When HbA1c Testing Is Unreliable in High Risk Cardiovascular Patients}, journal = {International Journal of Diabetes and Endocrinology}, volume = {2}, number = {1}, pages = {5-9}, doi = {10.11648/j.ijde.20170201.12}, url = {https://doi.org/10.11648/j.ijde.20170201.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20170201.12}, abstract = {To assess the evidence underlying Hemoglobin A1c (HbA1c) in patients with hemoglobinopathy and the use of this modality to evaluate confounders, sources of error, upcoming developments and reach evidence-based conclusions on their optimal use in patients who require tight glucose control. This was a retrospective chart review of 7 patients with data collected between the years 2004 - 2009. Participants were selected based on the criteria that they were 1) diagnosed with Type 2 Diabetes Mellitus; 2) patients of the North Florida Thyroid Center for at least one year; and 3) had hemoglobinopathy. These patients were selected using electronic medical records (EMR). Researchers were blinded of patients’ gender, race and any other personal identifiers. A random search was performed for hemoglobinopathy within physician patient database. Assessing glycemia in diabetics can be a challenge, in particular subgroup patients with hemoglobinopathies face several pitfalls that can implicate glycemia assessment rather difficult. Our results suggest there may be a discrepancy between mean blood glucose and A1C levels of individuals with a hemoglobinopathy in small cohorts at risk of cardiovascular demise.}, year = {2017} }
TY - JOUR T1 - Assessment of Glycemic Control and Hemoglobinopathy: When HbA1c Testing Is Unreliable in High Risk Cardiovascular Patients AU - Clauden Louis Y1 - 2017/03/15 PY - 2017 N1 - https://doi.org/10.11648/j.ijde.20170201.12 DO - 10.11648/j.ijde.20170201.12 T2 - International Journal of Diabetes and Endocrinology JF - International Journal of Diabetes and Endocrinology JO - International Journal of Diabetes and Endocrinology SP - 5 EP - 9 PB - Science Publishing Group SN - 2640-1371 UR - https://doi.org/10.11648/j.ijde.20170201.12 AB - To assess the evidence underlying Hemoglobin A1c (HbA1c) in patients with hemoglobinopathy and the use of this modality to evaluate confounders, sources of error, upcoming developments and reach evidence-based conclusions on their optimal use in patients who require tight glucose control. This was a retrospective chart review of 7 patients with data collected between the years 2004 - 2009. Participants were selected based on the criteria that they were 1) diagnosed with Type 2 Diabetes Mellitus; 2) patients of the North Florida Thyroid Center for at least one year; and 3) had hemoglobinopathy. These patients were selected using electronic medical records (EMR). Researchers were blinded of patients’ gender, race and any other personal identifiers. A random search was performed for hemoglobinopathy within physician patient database. Assessing glycemia in diabetics can be a challenge, in particular subgroup patients with hemoglobinopathies face several pitfalls that can implicate glycemia assessment rather difficult. Our results suggest there may be a discrepancy between mean blood glucose and A1C levels of individuals with a hemoglobinopathy in small cohorts at risk of cardiovascular demise. VL - 2 IS - 1 ER -